Advertisement

Shire gains on Lotus Tissue Repair acquisition

Ireland-based pharmaceutical company Shire on Wednesday gained on news it had acquired Lotus Tissue Repair.

Ireland-based pharmaceutical company Shire on Wednesday gained on news it had acquired Lotus Tissue Repair.

Shire advanced 1.78% to 1,998.00p on Tuesday morning following its announcement about purchasing the US-based company for an undisclosed sum.

Lotus is focused on developing the first treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disorder that causes extremely fragile skin and recurrent blister formation.

Advertisement - Article continues below

The group's protein replacement therapy is in late pre-clinical development for the treatment of DEB.

Philip Vickers, Head of Research and Development at Shire Human Genetic Therapies, said the protein replacement therapy could potentially provide first-in-class disease-modifying treatment for children with the disorder.

Lotus Tissue Repair was founded in 2011 when it closed on a $26m in Series A financing round from venture capital firm Third Rock Investors.

The acquisition marks Shire's latest effort to strengthen its rare disease offering including the treatment of EB.

Shire is also working on ABH001, a regenerative medicine product under investigation as a skin substitute therapy for nonhealing wounds in EB patients.

"The acquisition actually has no negative consequences on ABH001. That's moving ahead at full speed. It's not being slowed down. We very clearly see these as being complementary in a number of ways," Vickers told GEN.

RD

Advertisement
Advertisement

Recommended

Visit/investments/investment-strategy/601044/broker-safety-your-questions-answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
Visit/investments/investment-strategy/600861/how-demographics-affects-stock-valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Visit/investments/stocks-and-shares/600863/sirius-minerals-anglo-american-takeover
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Visit/investments/stockmarkets/600634/why-investors-should-be-cautiously-bullish-for-2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Visit/investments/property/601606/house-prices-crash-uk-property-prices-falling-where-next
Property

House price crash: UK property prices are falling – so where next?

With UK property prices falling for the first time in eight years, are we about to see a house price crash? John Stepek looks at what’s behind the sli…
2 Jul 2020
Visit/investments/stockmarkets/601611/nasdaq-all-time-high-markets-and-the-real-economy
Stockmarkets

How can markets hit new record highs when the economy is in such a mess?

Despite the world being in the midst of a global pandemic, America's Nasdaq stock index just hit an all-time high. And it's not the only index on a bu…
3 Jul 2020
Visit/economy/inflation/601584/the-end-of-the-bond-bull-market-and-the-return-of-inflation
Inflation

The end of the bond bull market and the return of inflation

Central bank stimulus, surging post-lockdown demand and the end of the 40-year bond bull market. It all points to inflation, says John Stepek. Here’s …
30 Jun 2020